MicroRNAs (miRNAs), as non-invasive and minimally expressed nucleic acid biomarkers, hold tremendous promise for early disease diagnostics. However, conventional detection methods such as PCR and RT-PCR are often limited by the extremely short length (~22 nucleotides) of miRNAs, which complicates primer design and introduces amplification bias or artifacts. Here, we report a novel, amplification-free, and highly sensitive surface-enhanced Raman scattering (SERS) platform for the rapid detection of femtomolar levels of miRNA in clinical samples. This portable, label-free SERS assay employs a plasmonic nanogap architecture formed by gold nanoparticles (AuNPs) self-assembled on a nanostructured gold-coated glass substrate. The resulting "hot spots" generate intense localized electromagnetic fields via surface plasmon resonance coupling, significantly enhancing the Raman signal of target miRNAs. We demonstrate this approach using both synthetic miRNA-25-3p and miRNA extracted from colorectal cancer cell lines (SW480), where miRNA-25-3p is known to be overexpressed. The detection protocol follows a two-step strategy: (1) magnetic bead-based isolation of target miRNA using biotinylated capture probes and streptavidin-coated beads, and (2) release and mixed with synthesized AuNPs then immobilization of the captured miRNA onto the gold slide for Raman analysis. Raman spectra were acquired using a portable MIRA XTR Raman spectrometer equipped with a 785 nm laser (100 mW), capturing distinct peaks corresponding to nucleic acid vibrational modes—such as C–O–P bending (838 and 860 cm⁻¹), adenine ring stretching (1339 cm⁻¹), guanine ring vibration (1533 cm⁻¹),and C=O overtone/combination bands of uracil (1771 and 1891 cm⁻¹). The platform achieved a good detection limit down to 100 fM with a linear signal response over a six-log dynamic range (1 μM–10 fM). Specificity tests using non-target miRNAs (miRNA-34a-5p andmiRNA-210-3p) showed negligible cross-reactivity, comparable to the no-template control. These findings underscore the assay’s high selectivity, sensitivity, and robustness, offering a promising field-deployable method for miRNA detection that overcomes the inherent limitations of amplification-based techniques. This SERS-based technology holds strong translational potential for point-of-care diagnostics in oncology and other disease contexts.